Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Strata Skin Sciences ( (SSKN) ) has provided an announcement.
On May 19, 2025, STRATA Skin Sciences announced a significant expansion of CPT codes for reimbursement of 308nm excimer laser treatments, which now include multiple inflammatory and autoimmune skin conditions beyond psoriasis. This change, reflecting over 20 years of clinical evidence, is expected to broaden market access from 10 million to over 30 million potential patients, reducing reimbursement barriers and supporting STRATA’s mission to provide non-drug dermatologic solutions. The update is anticipated to drive commercial growth and expand the use of STRATA’s XTRAC platform, benefiting patients, providers, and insurers.
The most recent analyst rating on (SSKN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Strata Skin Sciences stock, see the SSKN Stock Forecast page.
Spark’s Take on SSKN Stock
According to Spark, TipRanks’ AI Analyst, SSKN is a Neutral.
Strata Skin Sciences faces significant financial challenges with ongoing losses and issues in profitability, which weigh heavily on its overall score. The technical analysis provides a neutral outlook, while the valuation remains unattractive due to a negative P/E ratio. Positively, the earnings call highlighted strategic initiatives leading to growth areas like international sales and device expansion, offering a glimpse of potential improvements. However, stagnant revenue growth and potential tariff impacts continue to pose risks.
To see Spark’s full report on SSKN stock, click here.
More about Strata Skin Sciences
STRATA Skin Sciences is a medical technology company focused on developing, commercializing, and marketing innovative products for dermatologic conditions such as psoriasis, vitiligo, and acne. Their offerings include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System, which are provided through a unique Partnership Program in the U.S.
Average Trading Volume: 5,858
Technical Sentiment Signal: Strong Sell
Current Market Cap: $11.05M
For detailed information about SSKN stock, go to TipRanks’ Stock Analysis page.